About Us
Company Profile
Executive Management
Board of Directors
Clinical Advisory Board
Our Pipeline
Our Science
For Patients
Investors & Media
Overview
News & Press Releases
Presentations
Publications
Events
SEC Filings
Stock Quote & Chart
Executive Management
Board of Directors
Board Committees
Corporate Governance
Clinical Advisory Board
Analyst Coverage
RSS Feeds
Contact Us
Contact Us
About Us
Company Profile
Executive Management
Board of Directors
Clinical Advisory Board
Our Pipeline
Our Science
For Patients
Investors & Media
Overview
News & Press Releases
Presentations
Publications
Events
SEC Filings
Stock Quote & Chart
Executive Management
Board of Directors
Board Committees
Corporate Governance
Clinical Advisory Board
Analyst Coverage
RSS Feeds
Contact Us
Contact Us
Home
>
News
>
Introduction to SAB’s Unique DiversitAb™ Immunotherapy Platform
October 13, 2021
Introduction to SAB’s Unique DiversitAb™ Immunotherapy Platform
Share
SAB Biotherapeutics to Host Virtual R&D Day on October 13, 2021
October 6, 2021
SAB Biotherapeutics Announces First Patient Dosed in Phase 3 NIH ACTIV-2 Trial Evaluating SAB-185 for Treatment of COVID-19
October 4, 2021
SAB Biotherapeutics Appoints Russell Beyer Chief Financial Officer
September 28, 2021
